Jul. 27, 2021—A report of more than 23,000 health care workers and employees at Vanderbilt University Medical Center who received the Pfizer-BioNTech mRNA COVID-19 vaccine shows that a risk stratification screening mechanism for potential allergies to the vaccine worked exceedingly well as the vaccine program rolled out in December 2020.
Allergic reaction to first dose of an mRNA COVID-19 vaccine should not keep people from getting the second dose: study
Jul. 26, 2021—An immediate allergic reaction to the first dose of an mRNA COVID-19 vaccine — those manufactured by Moderna and Pfizer BioNTech — should not keep people from getting the second dose, a multi-hospital analysis shows.
Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
Jul. 12, 2018—A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.
Jan. 4, 2018—New findings from Vanderbilt suggest that blocking the migration of cells involved in asthma may represent a new approach for treating the respiratory condition.
Feb. 28, 2017—Hay fever can pose more of a challenge in Southern cities. Here’s why and what to do about it.